Magle Chemoswed Holding AB (publ) (OM: MAGLE)
Health Care · Life Sciences Tools & Services · SE
Skr0.40
-4.76% today · -98.2% 1Y
Magle Chemoswed Holding AB (publ) (OM: MAGLE) operates in the Life Sciences Tools & Services industry within the Health Care sector. The company is valued at $1.34M and employs 150 people.
Over the last twelve months the share price has lost 98.2%, trading between 0.39 and 23.60.
Tweenvest scores Magle Chemoswed Holding AB (publ) across four factors: quality 53/100, value 82/100, growth 68/100. Its strongest factor is value.
MAGLE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.34M
- Revenue (TTM)
- $28.45M
- P/E
- —
- EPS
- -12.72
- Dividend yield
- —
- Beta (5Y)
- 0.47
- 52-week high
- Skr23.60
- 52-week low
- Skr0.39
- Avg volume (3M)
- —
- Shares outstanding
- 30.26M
- Employees
- 150
- Next earnings
- —
About Magle Chemoswed Holding AB (publ)
Magle Chemoswed Holding AB (publ), based in Malmö, Sweden, specializes in the research, development, and manufacturing of products within the pharmaceutical chemistry and technology sectors. The company's core activities include the process development and production of Active Pharmaceutical Ingredients (APIs), as well as the innovation and manufacturing of advanced wound care and diagnostic products, primarily leveraging its proprietary degradable starch microsphere technology. Its API portfolio features Warfarin sodium, used as an anticoagulant; Melperone hydrochloride, an antipsychotic agent; Isradipine, a calcium channel blocker for hypertension; Amantadine sulfate, for central nervous system disorders; and Benserazide hydrochloride, utilized with L-Dopa in Parkinson's disease treatment. Furthermore, Magle Chemoswed offers a range of medical devices for advanced wound care, surgical diagnostics, and drug delivery. These include EmboCept S, a microsphere-based device for vascular occlusion in liver and lung tumors; SmartGel, an innovative non-allergenic hydrogel derived from their microsphere platform; SmartPAN, a diagnostic tool for detecting pancreatic fluid leakage during surgical procedures; and EmboCept M, designed for managing benign prostatic hyperplasia. The company provides contract services to the pharmaceutical and medical device industries. Founded in 1944, Magle Chemoswed Holding AB (publ) operates as a subsidiary of Magle AB.
- ISIN
- SE0014401014
- Founded
- 1944
- Listed since
- Jun 30, 2020
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Life Sciences Tools & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Thermo Fisher Scientific Inc.NYSE: TMO | $232.26B | $628.15 | -0.09% |
| Danaher CorporationNYSE: DHR | $151.82B | $215.97 | +0.40% |
| WuXi AppTec Co., Ltd.SHSE: 603259 | $71.35B | CN¥161.00 | +3.31% |
| Samsung Biologics Co.,Ltd.KOSE: A207940 | $51.75B | ₩1,551,000.00 | +0.19% |
| Lonza Group AGSWX: LONN | $51.65B | CHF593.80 | +1.02% |
| Agilent Technologies, Inc.NYSE: A | $43.71B | $154.77 | +0.87% |
| IQVIA Holdings Inc.NYSE: IQV | $42.70B | $259.42 | -0.32% |
| Waters CorporationNYSE: WAT | $40.72B | $414.44 | +0.90% |
Figures last refreshed Aug 18, 2026.